Application of Adaptive Design Methodology in Development of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Statistical Design and Simulations-Reference-Cited by-同舟云学术

Application of Adaptive Design Methodology in Development of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Statistical Design and Simulations

Published:2012-11 Issue:6 Volume:6 Page:1305-1318
ISSN:1932-2968
Container-title:Journal of Diabetes Science and Technology
language:en
Short-container-title:J Diabetes Sci Technol

Author:

Skrivanek Zachary¹,Berry Scott²,Berry Don²³,Chien Jenny¹,Geiger Mary Jane¹,Anderson James H.⁴,Gaydos Brenda⁵

Affiliation:

1. Lilly Diabetes, Eli Lilly and Company, Indianapolis, Indiana

2. Berry Consultants, Austin, Texas

3. The University of Texas M.D. Anderson Cancer Center, Houston, Texas

4. Symcopeia Company, Carmel, Indiana

5. Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana

Publisher

SAGE Publications

Subject

Biomedical Engineering,Bioengineering,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/193229681200600609

Reference18 articles.

1. An Adaptive, Dose-Finding, Seamless Phase 2/3 Study of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Trial Design and Baseline Characteristics

2. Bayesian Statistics and the Efficiency and Ethics of Clinical Trials

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exposure-Response–Based Multiattribute Clinical Utility Score Framework to Facilitate Optimal Dose Selection for Oncology Drugs;Journal of Clinical Oncology;2024-09-03

2. Comment: Response Adaptive Randomization in Practice;Statistical Science;2023-05-01

3. The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design;BMJ;2020-06-17

4. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design;Trials;2020-06-17

5. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency;Trials;2018-11-20